![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
LA Dykstra, DE Gmerek, G Winger and JH Woods
In rhesus monkeys, kappa opioid agonists have been shown to increase urinary output, increase tail-withdrawal latencies from warm water and produce distinct discriminative stimulus effects. In order to explore further the relation between these effects and activity at the kappa opioid receptor type, the antagonist activity of quadazocine against several kappa opioid agonists was examined with the tail-withdrawal and drug-discrimination procedures. Quadazocine dose dependently antagonized the increases in tail-withdrawal latency produced by the kappa agonists bremazocine, ethylketazocine and U-50, 488, as well as the discriminative stimulus effects of these drugs. The dose-ratio analysis of Schild revealed apparent pA2 values for quadazocine in combination with bremazocine, ethylketazocine and U-50, 488 of 6.1, 6.4 and 6.4, respectively, with the tail-withdrawal procedure and 6.3, 6.4 and 6.1, respectively, with the drug-discrimination procedure. Quadazocine also antagonized the effects of a mu agonist (morphine) in the tail-withdrawal procedure, and the apparent pA2 value for these data was 8.2. The activity of the mu-selective alkylating agent, beta- funaltrexamine (beta-FNA), was examined alone and in combination with the kappa agonist ethylketazocine in the urinary-output, tail- withdrawal and drug-discrimination procedures. At about 30 to 60 min postinjection, beta-FNA alone produced ethylketazocine-appropriate responding under the drug-discrimination procedure and increased urine output but did not increase tail-withdrawal latencies. At 24 to 48 hr postinjection, beta-FNA did not antagonize effects of ethylketazocine in any of the three procedures.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  C. A. Bowen, B. D. Fischer, N. K. Mello, and S. S. Negus Antagonism of the Antinociceptive and Discriminative Stimulus Effects of Heroin and Morphine by 3-Methoxynaltrexone and Naltrexone in Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 264 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Butelman, M. C. H. Ko, J. R. Traynor, J. A. Vivian, M.-J. Kreek, and J. H. Woods GR89,696: A Potent kappa -Opioid Agonist with Subtype Selectivity in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1049 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Carey and J. Bergman Enadoline Discrimination in Squirrel Monkeys: Effects of Opioid Agonists and Antagonists J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 215 - 223. [Abstract] [Full Text]
|
|
|
|
|
|
C. A. Paronis and J. Bergman Apparent pA2 Values of Benzodiazepine Antagonists and Partial Agonists in Monkeys J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1222 - 1229. [Abstract] [Full Text]
|
|
|
|
|
|
E. R. Butelman, T. J. Harris, A. Perez, and M.-J. Kreek Effects of Systemically Administered Dynorphin A(1-17) in Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 678 - 686. [Abstract] [Full Text]
|
|
|
|
|
|
R. C. Pitts, R. M. Allen, E. A. Walker, and L. A. Dykstra Clocinnamox Antagonism of the Antinociceptive Effects of Mu Opioids in Squirrel Monkeys J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1197 - 1206. [Abstract] [Full Text]
|
|
|
|
|
|
M.-C. Ko, E. R. Butelman, J. R. Traynor, and J. H. Woods Differentiation of Kappa Opioid Agonist-Induced Antinociception by Naltrexone Apparent pA2 Analysis in Rhesus Monkeys, J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 518 - 526. [Abstract] [Full Text]
|
|
|
|
|
|
E. R. Butelman, M.-C. Ko, K. Sobczyk-Kojiro, H. I. Mosberg, B. V. Bemmel, G. Zernig, and J. H. Woods Kappa-Opioid Receptor Binding Populations in Rhesus Monkey Brain: Relationship to an Assay of Thermal Antinociception J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 595 - 601. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Picker Discriminative Stimulus Effects of the Mixed-Opioid Agonist/Antagonist Dezocine: Cross-Substitution by Mu and Delta Opioid Agonists J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1009 - 1017. [Abstract] [Full Text]
|
|
|
|
|
|
H. R. Garner, T. F. Burke, C. D. Lawhorn, J. M. Stoner, and W. D. Wessinger Butorphanol-Mediated Antinociception in Mice: Partial Agonist Effects and Mu Receptor Involvement, J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1253 - 1261. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Negus, N. K. Mello, P. S. Portoghese, and C.-E. Lin Effects of Kappa Opioids on Cocaine Self-Administration by Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 44 - 55. [Abstract] [Full Text]
|
|
|
|
|
|
C. A. Paronis and J. H. Woods Ventilation in Morphine-Maintained Rhesus Monkeys. II: Tolerance to the Antinociceptive But Not the Ventilatory Effects of Morphine, J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 355 - 362. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
